Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Sell
19
MDXH Quote, Financials, Valuation and Earnings
Last price:
$3.3500
Seasonality move
:
-2.36%
Day range:
$3.2000 - $3.4000
52-week range:
$1.3500 - $5.3300
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.60x
P/B ratio:
23.64x
Volume:
98.4K
Avg. volume:
156.2K
1-year change:
45.02%
Market cap:
$165.8M
Revenue:
$90M
EPS (TTM):
-$0.64
Analysts' Opinion
-
Consensus RatingMDxHealth SA has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.0400, MDxHealth SA has an estimated upside of 110.15% from its current price of $3.3500.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.2000 representing 100% downside risk from its current price of $3.3500.
Fair Value
-
According to the consensus of 6 analysts, MDxHealth SA has 110.15% upside to fair value with a price target of $7.0400 per share.
MDXH vs. S&P 500
-
Over the past 5 trading days, MDxHealth SA has overperformed the S&P 500 by 6.75% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
MDxHealth SA does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
MDxHealth SA has grown year-over-year revenues for 0 quarters straight. In the most recent quarter MDxHealth SA reported revenues of $27.4M.
Earnings Growth
-
MDxHealth SA has grown year-over-year earnings for 4 quarters straight. In the most recent quarter MDxHealth SA reported earnings per share of -$0.16.
Enterprise value:
221.7M
EV / Invested capital:
2.78x
Price / LTM sales:
1.60x
EV / EBIT:
--
EV / Revenue:
2.15x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-15.79x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$61.2M
Return On Assets:
-20.03%
Net Income Margin (TTM):
-30.5%
Return On Equity:
-548.42%
Return On Invested Capital:
-39.3%
Operating Margin:
-12.67%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $63.7M | $84.7M | $103.1M | $23.3M | $27.4M | |
| Gross Profit | $26M | $47.6M | $61.2M | $12.9M | $16.6M | |
| Operating Income | -$30.5M | -$26.4M | -$14.1M | -$6.1M | -$3.5M | |
| EBITDA | -$28.7M | -$19.5M | -$5.1M | -$4M | -$1.2M | |
| Diluted EPS | -$1.26 | -$1.53 | -$0.64 | -$0.40 | -$0.16 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $40.9M | $45.6M | $70.2M | $58.2M | |
| Total Assets | -- | $122.6M | $135.7M | $157.4M | $154.3M | |
| Current Liabilities | -- | $19.3M | $18.8M | $45.5M | $51.2M | |
| Total Liabilities | -- | $101.1M | $117.9M | $140.4M | $162.5M | |
| Total Equity | -- | $21.5M | $17.8M | $17M | -$8.3M | |
| Total Debt | -- | -- | $40.1M | $54.9M | $87.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$23.8M | -$27.7M | -$12.7M | -$7.7M | -$719.4K | |
| Cash From Investing | -$6.3M | -$2.9M | -$23.3M | -$237.6K | -$1.3M | |
| Cash From Financing | $34.5M | $47.3M | $17.5M | $36.1M | $1.1M | |
| Free Cash Flow | -$30.6M | -$30.7M | -$14M | -$7.9M | -$1M | |
MDXH
Sector
Market Cap
$165.8M
$28.2M
Price % of 52-Week High
62.85%
50.25%
Dividend Yield
0%
0%
Shareholder Yield
-3.84%
-1.54%
1-Year Price Total Return
45.02%
-18.1%
Beta (5-Year)
-557,066.812
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.3188
200-day SMA
Buy
Level
$2.8864
Bollinger Bands (100)
Sell
Level
3.1955 - 4.4355
Chaikin Money Flow
Sell
Level
-2.8M
20-day SMA
Sell
Level
$3.4010
Relative Strength Index (RSI14)
Sell
Level
43.2339
ADX Line
Sell
Level
28.2767
Williams %R
Neutral
Level
-49.2386
50-day SMA
Sell
Level
$3.8478
MACD (12, 26)
Sell
Level
-0.1145
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
1.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.5424)
Sell
CA Score
(Annual)
Level (-2.9192)
Buy
Beneish M-Score
(Annual)
Level (-2.8099)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (4.7691)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (8)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
MDxHealth SA is a commercial-stage precision diagnostics company, which engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. It operates through the following geographical segments: United States of America, Europe and Rest of the World. The firm offers ConfirmMDx, SelectMDx, AssureMDx, InformMDx, SelectMDx, and MonitorMDx. The company was founded by Herman Spolders and Philip S. Devine on January 10, 2003 and is headquartered in Herstal, Belgium.
Stock Forecast FAQ
In the current month, MDXH has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MDXH average analyst price target in the past 3 months is $7.0400.
-
Where Will MDxHealth SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that MDxHealth SA share price will rise to $7.0400 per share over the next 12 months.
-
What Do Analysts Say About MDxHealth SA?
Analysts are divided on their view about MDxHealth SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MDxHealth SA is a Sell and believe this share price will drop from its current level to $4.2000.
-
What Is MDxHealth SA's Price Target?
The price target for MDxHealth SA over the next 1-year time period is forecast to be $7.0400 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MDXH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for MDxHealth SA is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MDXH?
You can purchase shares of MDxHealth SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MDxHealth SA shares.
-
What Is The MDxHealth SA Share Price Today?
MDxHealth SA was last trading at $3.3500 per share. This represents the most recent stock quote for MDxHealth SA. Yesterday, MDxHealth SA closed at $3.3500 per share.
-
How To Buy MDxHealth SA Stock Online?
In order to purchase MDxHealth SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get MDXH Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MDXH
Sector
P/E ratio
--
23.92x
PEG ratio
--
-0.01x
P/B ratio
23.64x
1.83x
Price / LTM sales
1.60x
1.61x
Growth Metrics
MDXH
Sector
Revenue growth
17.65%
4.6%
Earnings growth
59.55%
10.88%
Revenue (5-year growth)
50.19%
6.46%
Earnings forecast
-$0.26
-$0.21
Profitability
MDXH
Sector
Profitability FY 2024
$50.2M
$3.5M
Return on invested capital
-39.3%
-31.84%
Return on assets
-20.03%
-27.96%
Return on equity
-548.42%
-37.63%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Feb
25
Estimated Next Earnings Date
Feb
11
Balance Sheet
MDXH
Sector
Total cash
$32M
$26.3M
Short term investments
--
$25.7M
Total assets
$157.3M
$76.9M
Long term debt
$87.9M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 18.81% over the past day.
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.
Buy
63
GLTO alert for Dec 30
Galecto, Inc. [GLTO] is down 12.13% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
